Pharma manufacturing news in brief
pharmafile | April 14, 2011 | News story | Manufacturing and Production | Cangene, Chirotech, Grand River Aseptic Manufacturing, Perrigo, West Pharmaceutical Services
India’s Dr Reddy’s Laboratories has opened a new headquarters for its UK subsidiary ChiroTech, along with a new purpose-built laboratory facility, at its site on the Cambridge Science Park.
The new 33,000 sq. ft. facility will provide a range of small molecule manufacturing and R&D services for both Dr Reddy’s and third-party drugmakers. It operates as part of the Custom Pharmaceutical Services (CPS) business unit at Dr Reddy’s.
Over-the-counter and generic medicines manufacturer Perrigo has taken a step down the recovery path for its manufacturing operations, after reporting that the US FDA has given its troubled facility in Allegan, Michigan, a clean bill of health. The resolution of quality problems at the plant means that Perrigo can now seek approval for products made there, including a generic version of Reckitt Benckiser’s cough preparation Mucinex which has been stalled for over a year.
Pharmaceutical component manufacturer West Pharmaceutical Services says it is expanding production capacity for its Daikyo Crystal Zenith syringe system, which is designed for delivering biopharmaceuticals, at its facility in Scottsdale, Arizona, USA. The company plans to add cleanroom and warehousing space which should allow it to manufacture and ship up to 20 million units a year. The company said the syringe system, introduced last year, is highly-resistant to glass delamination, which has caused a range of product recalls in recent months.
Canadian drugmaker Cangene has been forced to downsize its workforce because of decreased contract manufacturing activity on behalf of the US government. Most of the cuts will take place in Canada, and the US contract manufacturing operations of Cangene’s US subsidiary, Cangene bioPharma, are unaffected by the reorganisation. The company has already shed 60 jobs in recent months and says the latest round will take another 40 off its total headcount of around 800.
US start-up Grand River Aseptic Manufacturing has raised $5 million to help fund the setting up of contract production of clinical trial materials at a 12,000 sq. ft. facility in Grand Rapids, Michigan. The funds will be used to expand a sterile parenteral production unit at the plant, which focuses on manufacturing materials for pre-clinical, phase I and II clinical trials, and small-scale commercial production.
Phil Taylor
Related Content
FDA advisory committee votes in favour of OTC contraceptive pill
Perrigo Company has announced that the US Food and Drug Administration’s (FDA) Nonprescription Drugs Advisory …
Perrigo rejects $26 billion hostile Mylan takeover bid
Perrigo has rejected Mylan’s hostile $26 billion bid after a 60% majority of shareholders were …
Perrigo buys OTC products from GSK
In an all-cash move with no financial details disclosed Perrigo is buying a portfolio of …
